Cervical prophylaxis, or cervical cancer vaccine, bivalent and quadrivalent HPV vaccines are suitable for ages 9-45, and the nine-valent vaccine is suitable for women aged 16-26. The bivalent cervical cancer vaccine mainly targets human papillomavirus (HPV) subtypes 16 and 18, and can prevent 70% of cervical cancers. Quadrivalent cervical cancer vaccine mainly targets HPV subtypes 6, 11, 16, and 18, and can prevent 70% of cervical cancers and 90% of acromegaly. The nine-valent cervical cancer vaccine not only prevents all of the above, but also includes HPV subtypes 31, 33, 45, 52, and 58, preventing 70% of cervical cancers, 90% of condyloma acuminatum, and 80% of vaginal cancers. Compared with bivalent and quadrivalent cervical cancer vaccines, the nine-valent cervical cancer vaccine prevents a wider range of cervical cancers, but it is expensive, difficult to make an appointment, and has a stricter age restriction. If you only want to prevent cervical cancer, the bivalent vaccine can meet your needs. If you have the condition, it is recommended to get the nine-valent vaccine.